Neuron-Glia Interaction as a Possible Glue to Translate the Mind-Brain Gap: A Novel Multi-Dimensional Approach Toward Psychology and Psychiatry (R1) by Takahiro A. Kato et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSYCHIATRY
PERSPECTIVE ARTICLE
published: 21 October 2013
doi: 10.3389/fpsyt.2013.00139
Neuron-glia interaction as a possible glue to translate the
mind-brain gap: a novel multi-dimensional approach
toward psychology and psychiatry
Takahiro A. Kato1,2*, MotokiWatabe3 and Shigenobu Kanba1
1 Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 Innovation Center for Medical Redox Navigation, Kyushu University, Fukuoka, Japan
3 Department of Management, School of Business, Monash University, Sunway, Malaysia
Edited by:
Stefan Borgwardt, University of
Basel, Switzerland
Reviewed by:
R. Bruce Bolster, University of
Winnipeg, Canada
Gianluca Serafini, Sapienza University
of Rome, Italy
Gabriele Ende, Central Institute of
Mental Health, Germany
*Correspondence:
Takahiro A. Kato, Department of
Neuropsychiatry, Graduate School of
Medical Sciences, Kyushu University;
Innovation Center for Medical Redox
Navigation, Kyushu University, 3-1-1
Maidashi Higashi-ku, Fukuoka
812-8582, Japan
e-mail: takahiro@npsych.med.
kyushu-u.ac.jp
Neurons and synapses have long been the dominant focus of neuroscience, thus the
pathophysiology of psychiatric disorders has come to be understood within the neuronal
doctrine. However, the majority of cells in the brain are not neurons but glial cells includ-
ing astrocytes, oligodendrocytes, and microglia.Traditionally, neuroscientists regarded glial
functions as simply providing physical support and maintenance for neurons. Thus, in this
limited role glia had been long ignored. Recently, glial functions have been gradually inves-
tigated, and increasing evidence has suggested that glial cells perform important roles in
various brain functions. Digging up the glial functions and further understanding of these
crucial cells, and the interaction between neurons and glia may shed new light on clarifying
many unknown aspects including the mind-brain gap, and conscious-unconscious relation-
ships. We briefly review the current situation of glial research in the field, and propose a
novel translational research with a multi-dimensional model, combining various experimen-
tal approaches such as animal studies, in vitro & in vivo neuron-glia studies, a variety of
human brain imaging investigations, and psychometric assessments.
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INTRODUCTION
Neurons and synapses have long been the dominant focus of neu-
roscience, thus the pathophysiology of psychiatric disorders has
come to be understood within the neuronal doctrine. However, the
majority of cells in the brain are not neurons but glial cells includ-
ing astrocytes,oligodendrocytes, and microglia. Traditionally,neu-
roscientists regarded glial functions as simply providing physical
support and maintenance for neurons. Thus, in this limited role
glia had been long ignored (1). Recently, glial functions have been
gradually investigated, and increasing evidence has suggested that
glial cells perform important roles in various brain functions. Dig-
ging up the glial functions and further understanding of these
crucial cells, and the interaction between neurons and glia may
shed new light on clarifying many unknown aspects including
the mind-brain gap, and conscious-unconscious relationships. In
addition, glial pathophysiology may explain the possible impli-
cations for the pathogenesis of major psychiatric disorders. The
complexity of these aspects has yet to be well investigated. To
explore these physiological and pathological aspects, novel trans-
lational methods should be applied with a multi-dimensional
approach. Herein, we will briefly review the current situation of
glial research in the field,and propose a novel translational research
with a multi-dimensional model, combining various experimental
approaches such as animal studies, in vitro & in vivo neuron-
glia studies, a variety of human brain imaging investigations, and
psychological/psychiatric assessments.
GLIAL ROLES AND PATHOLOGY IN PSYCHIATRIC DISORDERS
Recent biological studies have been revealing the important roles
of glial cells in the process of neuropsychiatric disorders.
ASTROCYTES
Astrocytes are the most prevalent cell type in human brain and
contribute to the homeostasis of the brain by regulation of
neuronal metabolism, modulation of CNS inflammation, and
direct/indirect synaptic transmission such as MNDA receptors (2,
3). Astrocyte dysfunction has been critical for various neurologi-
cal disorders (4). Recent studies have shown abnormal expression
of glial fibrillary acid protein (GFAP) – a prototypical marker
of astrocyte – in postmortem brain of patients with schizo-
phrenia and major affective disorders (5–7). In addition, recent
rodent studies have suggested that astrocytes modulate anxious
and depressive behaviors (8, 9). On the other hand, direct modu-
lating effects of antidepressants have also been revealed (10–13).
Thus, astrocytes have been supposed to be a novel therapeutic tar-
get against various psychiatric disorders such as major affective
disorders and bipolar disorders (14, 15).
OLIGODENDROCYTES
Oligodendrocytes contribute to brain development and home-
ostasis in the brain by formulating myelin around axons, support-
ing neuronal networks in the brain. Recently, novel oligodendro-
cyte functions have been revealed such as monitoring neuronal
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activities via myelin-forming oligodendrocytes (16) and modu-
lating the conduction velocity of action potentials along axons
in the rat hippocampus (17). Dysfunctions of oligodendrocytes
have been indicated in psychiatric disorders, especially schizo-
phrenia and major affective disorders, from a series of genetic
studies (18, 19), postmortem studies (20–22), and diffusion tensor
imaging (DTI) studies (23–27). A novel animal model of schizo-
phrenia has been developed by treating a copper chelator, which
induces oligodendrocyte dysfunction and white matter abnormal-
ity as demyelination and schizophrenia-related behaviors (28, 29).
Cuprizone caused marked behavioral changes (working memory
deficit) indicated by the results of Y-maze task, which showed an
increase in the number of arm entries and a decrease in alterna-
tion behavior. These cuprizone-induced behavioral changes were
effectively prevented by chronic administration of quetiapine, an
atypical antipsychotic, which also diminished demyelination (28).
On the other hand, recent rodent studies have revealed the inter-
action between oligodendrocyte dysfunction and social behaviors.
Makinodan et al. reported that oligodendrocyte dysfunction is
formed by early-period social isolation and this maladaptive envi-
ronment induces working memory deficit associated with pre-
frontal cortex (PFC) function in later life (30). Liu et al. reported
that protracted social isolation of adult mice induces behavioral,
transcriptional, and ultrastructural changes in oligodendrocytes
of the PFC and impairs adult myelination (31).
MICROGLIA
Microglia are unique glial cells of mesodermal origin in the brain
that act as “brain macrophage”; immunological/inflammatory
players by moving around and releasing cytokines and free radi-
cals (32, 33). Thus, microglia have proved to play important roles
in various brain pathologies such as neurodegenerative diseases
and neuropathic pain via inducing inflammation and oxidative
stress (34–36). Recently, microglia have been revealed to have
direct contact with synapses and have proved to play crucial
roles in neuronal development through synaptic pruning (37–
39). Postmortem studies have shown microglial activation in the
brain of patients with schizophrenia and major affective disorders,
especially suicide victims (40–42). In addition, positron emission
tomography (PET) imaging studies using the peripheral benzodi-
azepine receptor bindings has shown that microglia are activated
in patients with schizophrenia (43–45) and autism (46). On the
other hand, minocycline, an antibiotic with inhibitory effects on
microglial cells, has been reported to have therapeutic effects
on schizophrenia and unipolar psychotic depression (47–49). In
addition, rodent in vitro studies have proved the novel effect of
psychotropic drugs (atypical antipsychotics such as risperidone
and aripiprazole, and antidepressants such as paroxetine and ser-
traline, both selective serotonin reuptake inhibitors) directly on
microglia by suppressing release of inflammatory cytokines and
free radicals (50–54). Thus, microglia are suggested to play key
roles in psychiatric disorders (53, 55, 56).
In the brain, neurons, astrocytes, oligodendrocytes, and
microglia are mutually communicating with each other, by direct-
contacting or via neurotransmitters and other various small mol-
ecules (57), and dysfunction of neuron-glia communication may
induce pathological conditions not only in neurodegenerative
diseases (58) but also in psychiatric conditions such as psychosis,
depression, and anxiety. The above-mentioned recent findings
strongly suggest that glial cells contribute to psychiatric disorders,
while the underlying mechanisms have not been clarified.
POSSIBLE GLIAL ROLES IN HUMANMENTAL FUNCTIONS
Until recently, the actual roles of glia in mental activities, especially
for healthy humans, have not been investigated. As the first step
to clarify this unexplored field, we have started to conduct a series
of social decision-making experiments with healthy human sub-
jects using minocycline, a microglial inhibitor (59–61). Healthy
Japanese adult males made a monetary decision about whether or
not to trust an anonymous partner after a 4-day oral administra-
tion of minocycline. Our first trial revealed that the minocycline
group showed a positive correlation between their monetary score
in trust game and their evaluation scores of others’ trustworthiness
in a questionnaire (Yamagishi’s General Trust Scale), but surpris-
ingly the placebo group did not (60). It would be rational to
consider the monetary and questionnaire score to be positively cor-
related because both scores measure the other’s trustworthiness,
but there was no positive correlation with the placebo group. The
questionnaire is measuring only conscious-level decision-making,
on the other hand the monetary score is measuring the final
decision-making affected by not only the conscious but also the
unconscious; suggesting that some unconscious noisy factors seem
to be affecting the placebo group. Treatment with minocycline, a
microglial inhibitor, has shown the positive correlation. There-
fore, this first trial has indicated that microglial activation may
cause “unconscious noises” against appropriate social decision-
making, and inhibiting microglial activity may reduce such noise
(60). In a next trial with larger samples, we additionally measured
the effects of anxiety and personality as candidates for “noise” fac-
tors, by using Temperament and Character Inventory (TCI) and
State-Trait Anxiety Inventory (STAI) (59). The monetary score in
trust game was significantly lower in the minocycline group. Inter-
estingly, participants’ ways of decision-making were significantly
shifted; certain personality traits (cooperativeness, reward depen-
dence, and self-directedness) proved to be the main modulating
factors of decision-making in the placebo group, on the other
hand the minocycline group was mainly modulated by state anxi-
ety and trustworthiness. Our results of the second trial suggest that
minocycline led to more situation-oriented decision-making, pos-
sibly by suppressing the effects of personality traits, and further-
more that personality and social behaviors might be modulated by
microglia. Interestingly, cooperativeness has proved to be the most
influential factor in the process of decision-making in the placebo
group of Japanese participants (59). It is widely known that coop-
erativeness and cooperative behaviors have been highly respected
and emphasized aspects in Japanese society. Thus, of course, these
aspects are ingrained during childhood by various sociocultural
experiences within family relationships, schools, and other areas
of society in Japan. Early-life events may activate human microglia,
establish a certain neurosynaptic connection, and this formation
may determine personality and personality-oriented social behav-
iors in later life (59, 62). If these experiments are conducted in
other countries with different sociocultural backgrounds, other
personality traits may be identified.
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In addition, we have recently reported a possible outcome that
minocycline, a microglial inhibitor, also reduces the risk of the
“honey trap”during economic exchanges between males× females
(61). Males tend to cooperate with physically attractive females
without careful evaluation of their trustworthiness. In our exper-
iment, young healthy male participants made risky choices
(whether or not to trust female partners, identified only by pho-
tograph, who had decided in advance to exploit the male partic-
ipants). The results show that trusting behavior in male partic-
ipants significantly increased in relation to the perceived attrac-
tiveness of the female partner, but attractiveness did not impact
trusting behavior in the minocycline group (61). These novel
effects of minocycline may highlight the unknown roles microglia
play in deeper human mental activities; microglia may modulate
our unconscious drives in various social settings. The above-
mentioned findings shed new light on the dark side of microglial
social/mental functions in humans, especially highlighting the role
of microglia for the unconscious. In the same way that Sigmund
Freud, the founder of psychoanalysis, proposed that our behav-
iors must be controlled by the unconscious world, microglia may
unconsciously control our behaviors. How do microglia act as fun-
damental mediators between the conscious and the unconscious
world? What do neurobiological mechanisms justify their eventual
role in bridging the gap between neuroscience and psychoanaly-
sis? Answers to the above questions are not yet clear, but we have
recently proposed a hypothesis creating a link between Freud’s
unconscious drives such as the death drive and microglial acti-
vation (62). For example, microglial maladaptive over-activation
in a certain brain region may activate human aggressive behav-
iors as a result of destructive drives [For the details, please see
our recent article; Ref. (62)]. In the brain, not only microglia but
also other glia such as astrocytes and oligodendrocytes exist, thus
complicated neuron-glia interactions may modulate our mental
activities including the unconscious (Figure 1). Further research
should be applied to clarify these unresolved questions.
After Freud’s theory of unconscious roles in behaviors which
was initially identified in the 1980s (63), Pribram and his col-
leagues have developed this theory in terms of a better articulated
model of neural computation (64, 65). In addition, recent neu-
ropsychoanalytic movements have been updating Freud’s theory
with modern sophisticated methods of cognitive neuroscience
(66–72). Thus, these recent approaches have been revealing the
underlying mechanisms of implicit processing in a variety of
information-processes including the social processes using rodent
experiments. At present, the link underlying mechanisms between
neuron-glia interactions and the conscious-unconscious relation-
ship is largely unsolved, and few experimental methods have been
developed to test these unknown brain mechanisms at either the
microscopic or macroscopic level. Unconscious processing needs
to be given a greater focus in terms of brain mechanisms. One pos-
sible solution is the novel ontogenetic approach; called“optogenet-
ics” (73–76). Optogenetics is a revolutionary technique involving
taking a light-activated gene (called a channel rhodopsin) targeted
into a single neuron type. This technique enables to clarify direct
interaction between activation of specific neuron in specific region
by light and the resulting outcomes such as behaviors and emo-
tional reactions at rodent level. A recent study has interestingly
FIGURE 1 |The mind-brain gap from a novel glial neuropsychoanalytic
perspective. The interaction between the mind and the brain has not been
well understood. Freud, the founder of psychoanalysis, proposed the
conception of mind structure models consisting of the following three
components: the ID (unconscious/instinctual drives), the EGO (the
exclusive apparatus of the conscious mind), and the SUPER-EGO (which
represses the id in order to avoid any disruptions of rational thought). The
existence and the significances of these mental components may be
explained by future understandings of the neuron-glia interactions. The
hypothetical interaction between the ID (unconscious drives) and microglia
has already been proposed in our recent theoretical paper (62).
shown that activation of specific neurons in hippocampus produce
a false memory in mice (77). Further technological developments
in modulating glial cells by light and in activating both neurons
and glial cells at the same time, by multiple fluorescent lights, may
shed new light on resolving unknown roles of glia and neuron-glia
interaction in behaviors and the conscious-unconscious. Func-
tional roles and pathological contributions of astrocyte, oligoden-
drocyte, and/or microglia in conscious or unconscious processes
have not been well understood, and we hypothesize that each cell
may differently contribute to these physical and/or pathological
processes in different brain regions such at the brainstem, limbic,
or thalamocortical region, respectively. Future developments in
optogenetics may clarify these unknown aspects.
LIMITATION AND FUTURE PERSPECTIVES OF NEURO-GLIA
RESEARCH ON PSYCHOLOGY AND PSYCHIATRY
To explore the above-mentioned hypothesis, further translational
research is needed. Several limitations should be made note of at
the present stage. At first, rodent studies focusing on the uncon-
scious are limiting. Even if the unconscious exists in rodents, it
seems to be impossible to measure the unconscious in rodents
devoid of human language capabilities. Therefore, to uncover the
unconscious mechanisms, we have no alternative method except
examining actual human subjects. We have no specific drugs to
modulate glial cells utilized in human, and minocycline is reported
to have other brain functions in addition to microglial inhibition
(78, 79). On the other hand, some brain imaging techniques enable
us to explore the unknown roles of glial cells such as DTI technique
and PET imaging using the peripheral benzodiazepine receptor
bindings, while the specificities of these imaging methods are not
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at satisfactory levels (80). On the other hand, we can reconsider
previous findings of brain imaging experiments. Functional MRI
(fMRI) is a brain imaging procedure measuring brain activity by
detecting associated changes in blood flow (81, 82). Outcomes of
fMRI have long been believed to monitor solely neuronal activ-
ities, because cerebral blood flow and neuronal activation have
been thought to be almost equivalent. However, not only neuronal
activities but also glial activities, especially astrocyte activities, rely
on cerebral blood flow. Therefore, at least to some extent, brain
activities expressed by fMRI may be showing a part of glial acti-
vation. In addition, MR spectroscopy (MRS) is one of the novel
imaging approaches to measure dynamic brain functions focusing
on metabolomics including glia-related molecules. For example,
myo-inositol, which can be measured by MRS, is regarded as a
marker of astrocyte activity (83). These imaging methods and
combination of these imaging techniques may shed new light
on clarifying unknown roles of glia in psychiatric disorders (84,
85). For example, activated microglia-derived myelin damage has
been indicated in the pathophysiology of schizophrenia by rodent
experimental models (28, 29, 86, 87), while it is not confirmed in
human subjects. Combination of human DTI and PET may clarify
the mutual interaction between microglial activation and myelin
damage in schizophrenia patients. On the other hand, connectiv-
ity of each brain region has been important in the understanding
of the roles of brain functions from the era of Hughlings Jackson.
fMRI studies have revealed the importance of these aspects (88,
89), and the recent development of DTI is showing us the signif-
icance of more complicated brain networks focusing on not only
neurons but also glial cells such as oligodendrocytes (90, 91).
Finally, we propose the multi-dimensional approach to clarify
the underlying brain mechanisms of mental functions includ-
ing the unconscious (Figure 2). Based on our discussion, we
believe that not only neurons but also glial cells have a vital
role in the process of mental activities, a novel approach focus-
ing on neuron-glia interactions should be applied. Combination
of brain imaging techniques focusing on both neurons and glial
cells should be applied (24, 26, 27, 43–46, 92–94). The most sig-
nificant limitation in human brain research is that we cannot
obtain living brain cells, including glial cells, from living human
subjects from an ethical perspective. Presently, we can apply an
alternative method; human brain cells such as neuronal cells can
be established from somatic cells (not from the brain) such as
skin fibroblasts by utilizing the gene-modification technique of
FIGURE 2 | A novel multi-dimensional approach toward psychology &
psychiatry.
induced pluripotent stem (iPS) cells. In addition, recently, neu-
ronal cells are more easily established from directly conversion
of human skin fibroblasts, called induced neuronal (iN) cells
(95–99). Novel methods of establishing glial cells are strongly
warranted based on iPS or direct conversion techniques in the
near future. Multi-dimensional aspects of same human subjects,
from genes, blood, brain imaging, psychometrics, social function,
unconscious functions, psychodynamic assessments to molecu-
lar functions of somatic tissue-derived neuronal and glial cells,
should be investigated and analyzed together (Figure 2). This
approach may explore the novel roles of glial cells in various
human mental activities including the unconscious. The appli-
cation of this method for psychiatric patients should also be
encouraged in the establishment of novel diagnostic methods and
novel therapies.
ACKNOWLEDGMENTS
This work was supported by Grant-in-Aid for Scientific Research
on (1) Innovative Areas “Glia Assembly” (No. 25117011) of The
Ministry of Education, Culture, Sports, Science, and Technology,
Japan, (2) the Japan Society for the Promotion of Science (No.
24650227), and (3) the Health and Labor Sciences Research Grant
No. [H 24-Seishin-Jitsuyouka (Seishin)-Ippan-001].
REFERENCES
1. Miller G. Neuroscience.
The dark side of glia. Sci-
ence (2005) 308:778–81.
doi:10.1126/science.308.5723.778
2. Halassa MM, Fellin T, Haydon PG.
The tripartite synapse: roles for glio-
transmission in health and disease.
Trends Mol Med (2007) 13:54–63.
doi:10.1016/j.molmed.2006.12.005
3. Sofroniew MV, Vinters HV. Astro-
cytes: biology and pathology. Acta
Neuropathol (2010) 119:7–35. doi:
10.1007/s00401-009-0619-8
4. Seifert G, Schilling K, Steinhauser
C. Astrocyte dysfunction in neu-
rological disorders: a molecular
perspective. Nat Rev Neurosci
(2006) 7:194–206. doi:10.1038/
nrn1870
5. Altshuler LL, Abulseoud OA,
Foland-Ross L, Bartzokis G, Chang
S, Mintz J, et al. Amygdala astrocyte
reduction in subjects with major
depressive disorder but not bipolar
disorder. Bipolar Disord (2010)
12:541–9. doi:10.1111/j.1399-5618.
2010.00838.x
6. Feresten AH, Barakauskas V, Ypsi-
lanti A, Barr AM, Beasley CL.
Increased expression of glial fib-
rillary acidic protein in prefrontal
cortex in psychotic illness. Schizo-
phr Res (2013) 150(1):252–7. doi:
10.1016/j.schres.2013.07.024
7. Rajkowska G, Stockmeier CA.
Astrocyte pathology in major
depressive disorder: insights from
human postmortem brain tis-
sue. Curr Drug Targets (2013)
14(11):1225–36. doi:10.2174/
13894501113149990156
8. Cao X, Li LP, Wang Q, Wu
Q, Hu HH, Zhang M, et al.
Astrocyte-derived ATP modulates
depressive-like behaviors. Nat Med
(2013) 19:773–7. doi:10.1038/nm.
3162
9. Quesseveur G, David DJ, Gail-
lard MC, Pla P, Wu MV, Nguyen
HT, et al. BDNF overexpression in
mouse hippocampal astrocytes pro-
motes local neurogenesis and elicits
anxiolytic-like activities. Transl Psy-
chiatry (2013) 3:e253. doi:10.1038/
tp.2013.30
Frontiers in Psychiatry | Neuropsychiatric Imaging and Stimulation October 2013 | Volume 4 | Article 139 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kato et al. Mind-brain translation by neuron-glia interaction
10. Hashioka S. Antidepressants and
neuroinflammation: can antide-
pressants calm glial rage down?Mini
Rev Med Chem (2011) 11:555–64.
doi:10.2174/138955711795906888
11. Hisaoka K, Tsuchioka M, Yano R,
Maeda N, Kajitani N, Morioka
N, et al. Tricyclic antidepres-
sant amitriptyline activates fibrob-
last growth factor receptor signal-
ing in glial cells: involvement in
glial cell line-derived neurotrophic
factor production. J Biol Chem
(2011) 286:21118–28. doi:10.1074/
jbc.M111.224683
12. Kajitani N, Hisaoka-Nakashima
K, Morioka N, Okada-Tsuchioka
M, Kaneko M, Kasai M, et al.
Antidepressant acts on astrocytes
leading to an increase in the
expression of neurotrophic/growth
factors: differential regulation of
FGF-2 by noradrenaline. PLoS
One (2012) 7:e51197. doi:10.1371/
journal.pone.0051197
13. Kittel-Schneider S, Kenis G, Schek
J, Van Den Hove D, Prickaerts
J, Lesch KP, et al. Expression
of monoamine transporters, nitric
oxide synthase 3, and neurotrophin
genes in antidepressant-stimulated
astrocytes. Front Psychiatry (2012)
3:33. doi:10.3389/fpsyt.2012.00033
14. Steiner J, Bogerts B, Sarnyai Z, Wal-
ter M, Gos T, Bernstein HG, et
al. Bridging the gap between the
immune and glutamate hypotheses
of schizophrenia and major depres-
sion: potential role of glial NMDA
receptor modulators and impaired
blood-brain barrier integrity. World
J Biol Psychiatry (2012) 13:482–92.
doi:10.3109/15622975.2011.583941
15. Sanacora G, Banasr M. From patho-
physiology to novel antidepressant
drugs: glial contributions to the
pathology and treatment of mood
disorders. Biol Psychiatry (2013)
73:1172–9. doi:10.1016/j.biopsych.
2013.03.032
16. Micu I, Ridsdale A, Zhang L,
Woulfe J, Mcclintock J, Brantner
CA, et al. Real-time measurement of
free Ca2+ changes in CNS myelin
by two-photon microscopy. Nat
Med (2007) 13:874–9. doi:10.1038/
nm1568
17. Yamazaki Y, Hozumi Y, Kaneko K,
Sugihara T, Fujii S, Goto K, et al.
Modulatory effects of oligodendro-
cytes on the conduction velocity
of action potentials along axons
in the alveus of the rat hip-
pocampal CA1 region. Neuron Glia
Biol (2007) 3:325–34. doi:10.1017/
S1740925X08000070
18. Tkachev D, Mimmack ML, Ryan
MM, Wayland M, Freeman T,
Jones PB, et al. Oligodendro-
cyte dysfunction in schizophre-
nia and bipolar disorder. Lancet
(2003) 362:798–805. doi:10.1016/
S0140-6736(03)14289-4
19. McCullumsmith RE, Gupta D,
Beneyto M, Kreger E, Haroutun-
ian V, Davis KL, et al. Expres-
sion of transcripts for myelination-
related genes in the anterior cingu-
late cortex in schizophrenia. Schiz-
ophr Res (2007) 90:15–27. doi:10.
1016/j.schres.2006.11.017
20. Uranova NA, Vostrikov VM,
Orlovskaya DD, Rachmanova VI.
Oligodendroglial density in the
prefrontal cortex in schizophre-
nia and mood disorders: a study
from the Stanley Neuropathology
Consortium. Schizophr Res (2004)
67:269–75. doi:10.1016/S0920-
9964(03)00181-6
21. Uranova NA, Vostrikov VM,
Vikhreva OV, Zimina IS, Kolomeets
NS, Orlovskaya DD. The role
of oligodendrocyte pathology in
schizophrenia. Int J Neuropsy-
chopharmacol (2007) 10:537–45.
doi:10.1017/S1461145707007626
22. Bernstein HG, Steiner J, Bogerts
B. Glial cells in schizophrenia:
pathophysiological significance and
possible consequences for ther-
apy. Expert Rev Neurother (2009)
9:1059–71. doi:10.1586/ern.09.59
23. Price SJ, Jena R, Burnet NG,
Hutchinson PJ, Dean AF, Pena A, et
al. Improved delineation of glioma
margins and regions of infiltra-
tion with the use of diffusion
tensor imaging: an image-guided
biopsy study. AJNR Am J Neurora-
diol (2006) 27:1969–74.
24. Schlosser RG, Nenadic I, Wagner
G, Gullmar D, Von Consbruch K,
Kohler S, et al. White matter abnor-
malities and brain activation in
schizophrenia: a combined DTI and
fMRI study. Schizophr Res (2007)
89:1–11. doi:10.1016/j.schres.2006.
09.007
25. Miyata J, Hirao K, Namiki C, Fuji-
wara H, Shimizu M, Fukuyama
H, et al. Reduced white matter
integrity correlated with cortico-
subcortical gray matter deficits
in schizophrenia. Schizophr Res
(2009) 111:78–85. doi:10.1016/j.
schres.2009.03.010
26. Kubota M, Miyata J, Yoshida H,
Hirao K, Fujiwara H, Kawada R,
et al. Age-related cortical thin-
ning in schizophrenia. Schizophr
Res (2011) 125:21–9. doi:10.1016/j.
schres.2010.10.004
27. Kubota M, Miyata J, Sasamoto A,
Sugihara G,Yoshida H, Kawada R, et
al. Thalamocortical disconnection
in the orbitofrontal region asso-
ciated with cortical thinning in
schizophrenia. JAMA Psychiatry
(2013) 70:12–21. doi:10.1001/
archgenpsychiatry.2012.1023
28. Xiao L, Xu H, Zhang Y, Wei Z, He J,
Jiang W, et al. Quetiapine facilitates
oligodendrocyte development and
prevents mice from myelin break-
down and behavioral changes. Mol
Psychiatry (2008) 13:697–708. doi:
10.1038/sj.mp.4002064
29. Zhang Y, Xu H, Jiang W, Xiao
L, Yan B, He J, et al. Quetiap-
ine alleviates the cuprizone-induced
white matter pathology in the brain
of C57BL/6 mouse. Schizophr Res
(2008) 106:182–91. doi:10.1016/j.
schres.2008.09.013
30. Makinodan M, Rosen KM, Ito S,
Corfas G. A critical period for
social experience-dependent oligo-
dendrocyte maturation and myeli-
nation. Science (2012) 337:1357–60.
doi:10.1126/science.1220845
31. Liu J, Dietz K, Deloyht JM, Pedre
X, Kelkar D, Kaur J, et al. Impaired
adult myelination in the prefrontal
cortex of socially isolated mice. Nat
Neurosci (2012) 15:1621–3. doi:10.
1038/nn.3263
32. Block ML, Zecca L, Hong JS.
Microglia-mediated neurotoxicity:
uncovering the molecular mech-
anisms. Nat Rev Neurosci (2007)
8:57–69. doi:10.1038/nrn2038
33. Hanisch UK, Kettenmann H.
Microglia: active sensor and
versatile effector cells in the
normal and pathologic brain.
Nat Neurosci (2007) 10:1387–94.
doi:10.1038/nn1997
34. Graeber MB, Streit WJ. Microglia:
biology and pathology. Acta Neu-
ropathol (2010) 119:89–105. doi:10.
1007/s00401-009-0622-0
35. Inoue K, Tsuda M. Microglia
and neuropathic pain. Glia (2009)
57:1469–79. doi:10.1002/glia.20871
36. Kettenmann H, Hanisch UK,
Noda M, Verkhratsky A. Phys-
iology of microglia. Phys-
iol Rev (2011) 91:461–553.
doi:10.1152/physrev.00011.2010
37. Wake H, Moorhouse AJ, Jinno
S, Kohsaka S, Nabekura J. Rest-
ing microglia directly monitor
the functional state of synapses
in vivo and determine the fate
of ischemic terminals. J Neurosci
(2009) 29:3974–80. doi:10.1523/
JNEUROSCI.4363-08.2009
38. Paolicelli RC, Bolasco G, Pagani F,
Maggi L, Scianni M, Panzanelli P,
et al. Synaptic pruning by microglia
is necessary for normal brain devel-
opment. Science (2011) 333:1456–8.
doi:10.1126/science.1202529
39. Schafer DP, Lehrman EK, Kautz-
man AG, Koyama R, Mardinly
AR, Yamasaki R, et al. Microglia
sculpt postnatal neural circuits
in an activity and complement-
dependent manner. Neuron (2012)
74:691–705. doi:10.1016/j.neuron.
2012.03.026
40. Radewicz K, Garey LJ, Gentle-
man SM, Reynolds R. Increase
in HLA-DR immunoreactive
microglia in frontal and temporal
cortex of chronic schizophrenics.
J Neuropathol Exp Neurol (2000)
59:137–50.
41. Steiner J, Mawrin C, Ziegeler A,
Bielau H, Ullrich O, Bernstein
HG, et al. Distribution of HLA-
DR-positive microglia in schiz-
ophrenia reflects impaired cere-
bral lateralization. Acta Neuropathol
(2006) 112:305–16. doi:10.1007/
s00401-006-0090-8
42. Steiner J, Bielau H, Brisch R,
Danos P, Ullrich O, Mawrin C, et
al. Immunological aspects in the
neurobiology of suicide: elevated
microglial density in schizophre-
nia and depression is associated
with suicide. J Psychiatr Res (2008)
42:151–7. doi:10.1016/j.jpsychires.
2006.10.013
43. van Berckel BN, Bossong MG,
Boellaard R, Kloet R, Schuitemaker
A, Caspers E, et al. Microglia
activation in recent-onset schiz-
ophrenia: a quantitative (R)-
[11C]PK11195 positron emis-
sion tomography study. Biol
Psychiatry (2008) 64:820–2.
doi:10.1016/j.biopsych.2008.04.025
44. Doorduin J, De Vries EF, Willem-
sen AT, De Groot JC, Dierckx
RA, Klein HC. Neuroinflamma-
tion in schizophrenia-related psy-
chosis: a PET study. J Nucl
Med (2009) 50:1801–7. doi:10.
2967/jnumed.109.066647
45. Takano A, Arakawa R, Ito H, Tateno
A, Takahashi H, Matsumoto R,
et al. Peripheral benzodiazepine
receptors in patients with chronic
schizophrenia: a PET study with
[11C]DAA1106. Int J Neuropsy-
chopharmacol (2010) 13:943–50.
doi:10.1017/S1461145710000313
46. Suzuki K, Sugihara G, Ouchi Y,
Nakamura K, Futatsubashi M,
Takebayashi K, et al. Microglial
activation in young adults with
autism spectrum disorder. JAMA
Psychiatry (2013) 70:49–58.
doi:10.1001/jamapsychiatry.2013.
272
47. Levkovitz Y, Mendlovich S, Riwkes
S, Braw Y, Levkovitch-Verbin H,
Gal G, et al. A double-blind, ran-
domized study of minocycline for
www.frontiersin.org October 2013 | Volume 4 | Article 139 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kato et al. Mind-brain translation by neuron-glia interaction
the treatment of negative and cog-
nitive symptoms in early-phase
schizophrenia. J Clin Psychiatry
(2010) 71:138–49. doi:10.4088/JCP.
08m04666yel
48. Chaudhry IB, Hallak J, Husain N,
Minhas F, Stirling J, Richardson P,
et al. Minocycline benefits negative
symptoms in early schizophrenia: a
randomised double-blind placebo-
controlled clinical trial in patients
on standard treatment. J Psy-
chopharmacol (2012) 26:1185–93.
doi:10.1177/0269881112444941
49. Miyaoka T, Wake R, Furuya M,
Liaury K, Ieda M, Kawakami K, et
al. Minocycline as adjunctive ther-
apy for patients with unipolar psy-
chotic depression: an open-label
study. Prog Neuropsychopharmacol
Biol Psychiatry (2012) 37:222–6.
doi:10.1016/j.pnpbp.2012.02.002
50. Kato T, Monji A, Hashioka S,
Kanba S. Risperidone significantly
inhibits interferon-gamma-induced
microglial activation in vitro. Schiz-
ophr Res (2007) 92:108–15. doi:10.
1016/j.schres.2007.01.019
51. Kato T, Mizoguchi Y, Monji A,
Horikawa H, Suzuki SO, Seki Y, et
al. Inhibitory effects of aripipra-
zole on interferon-gamma-induced
microglial activation via intracellu-
lar Ca2+ regulation in vitro. J Neu-
rochem (2008) 106:815–25. doi:10.
1111/j.1471-4159.2008.05435.x
52. Horikawa H, Kato TA, Mizoguchi
Y, Monji A, Seki Y, Ohkuri T,
et al. Inhibitory effects of SSRIs
on IFN-gamma induced microglial
activation through the regulation
of intracellular calcium. Prog Neu-
ropsychopharmacol Biol Psychiatry
(2010) 34:1306–16. doi:10.1016/j.
pnpbp.2010.07.015
53. Kato TA, Monji A, Mizoguchi Y,
Hashioka S, Horikawa H, Seki Y,
et al. Anti-inflammatory proper-
ties of antipsychotics via microglia
modulations: are antipsychotics a
“fire extinguisher” in the brain
of schizophrenia? Mini Rev Med
Chem (2011) 11:565–74. doi:10.
2174/138955711795906941
54. Kato TA, Monji A, Yasukawa K,
Mizoguchi Y, Horikawa H, Seki
Y, et al. Aripiprazole inhibits
superoxide generation from
phorbol-myristate-acetate (PMA)-
stimulated microglia in vitro:
implication for antioxidative psy-
chotropic actions via microglia.
Schizophr Res (2011) 129:172–82.
doi:10.1016/j.schres.2011.03.019
55. Monji A, Kato T, Kanba S. Cytokines
and schizophrenia: microglia
hypothesis of schizophrenia.
Psychiatry Clin Neurosci (2009)
63:257–65. doi:10.1111/j.1440-
1819.2009.01945.x
56. Kato TA, Yamauchi Y, Horikawa H,
Monji A, Mizoguchi Y, Seki Y, et
al. Neurotransmitters, psychotropic
drugs and microglia: clinical impli-
cations for psychiatry. Curr Med
Chem (2013) 20:331–44. doi:10.
2174/0929867311320030003
57. Verkhratsky A, Kirchhoff F.
Glutamate-mediated neuronal-
glial transmission. J Anat (2007)
210:651–60. doi:10.1111/j.1469-
7580.2007.00734.x
58. Gibson GE, Starkov A, Blass JP,
Ratan RR, Beal MF. Cause and
consequence: mitochondrial dys-
function initiates and propagates
neuronal dysfunction, neuronal
death and behavioral abnormali-
ties in age-associated neurodegener-
ative diseases. Biochim Biophys Acta
(2010) 1802:122–34. doi:10.1016/j.
bbadis.2009.08.010
59. Kato TA, Watabe M, Tsuboi S,
Ishikawa K, Hashiya K, Monji A, et
al. Minocycline modulates human
social decision-making: possible
impact of microglia on personality-
oriented social behaviors. PLoS
One (2012) 7:e40461. doi:10.1371/
journal.pone.0040461
60. Watabe M, Kato TA, Monji A,
Horikawa H, Kanba S. Does
minocycline, an antibiotic with
inhibitory effects on microglial acti-
vation, sharpen a sense of trust
in social interaction? Psychophar-
macology (2012) 220:551–7. doi:10.
1007/s00213-011-2509-8
61. Watabe M, Kato TA, Tsuboi S,
Ishikawa K, Hashiya K, Monji A,
et al. Minocycline, a microglial
inhibitor, reduces “honey trap” risk
in human economic exchange. Sci
Rep (2013) 3:1685. doi:10.1038/
srep01685
62. Kato TA, Kanba S. Are microglia
minding us? Digging up the
unconscious mind-brain relation-
ship from a neuropsychoanalytic
approach. Front Hum Neurosci
(2013) 7:13. doi:10.3389/fnhum.
2013.00013
63. Freud S. Project for a scientific psy-
chology. In: Strachey J, editor. The
Standard Edition of the Complete
Psychological Works of Sigmund
Freud, Volume I (1886-1899):
Pre-Psycho-Analytic Publications
and Unpublished Drafts. London:
The Hogarth Press (1950/1895).
p. 281–391.
64. Pribram KH, Gill MM. Freud’s
“Project” Re-assessed. London:
Hutchinson (1976).
65. Pribram KH. Freud’s “project” and
the mind-brain issue. J Nerv Ment
Dis (1978) 166:743–52. doi:10.
1097/00005053-197810000-00008
66. Fonagy P. Attachment Theory and
Psychoanalysis. New York: Other
Press (2001).
67. Solms M, Lechevalier B. Neuro-
sciences and psychoanalysis. Int J
Psychoanal (2002) 83:233–7. doi:10.
1516/X9LD-JPCE-KKDR-BPU5
68. Solms M, Turnbull O. The Brain
and the Inner World: An Introduc-
tion to the Neuroscience of Subjective
Experience. New York: Other Press
(2002).
69. Panksepp J. Neuro-psychoanalysis
may enliven the mindbrain sciences.
Cortex (2007) 43:1106–7. doi:10.
1016/S0010-9452(08)70714-7 dis-
cussion 1116–1121,
70. Arminjon M, Ansermet F, Mag-
istretti P. The homeostatic
psyche: Freudian theory and
somatic markers. J Physiol Paris
(2010) 104:272–8. doi:10.1016/j.
jphysparis.2010.08.006
71. Northoff G. Neuropsychoanalysis in
Practice: Brain, Self and Objects.
New York: Oxford University Press
(2011).
72. Panksepp J, Solms M. What is
neuropsychoanalysis? Clinically rel-
evant studies of the minded brain.
Trends Cogn Sci (2012) 16:6–8. doi:
10.1016/j.tics.2011.11.005
73. Boyden ES, Zhang F, Bamberg E,
Nagel G, Deisseroth K. Millisecond-
timescale, genetically targeted opti-
cal control of neural activity. Nat
Neurosci (2005) 8:1263–8. doi:10.
1038/nn1525
74. Deisseroth K, Feng G, Majew-
ska AK, Miesenbock G, Ting A,
Schnitzer MJ. Next-generation opti-
cal technologies for illuminating
genetically targeted brain circuits.
J Neurosci (2006) 26:10380–6.
doi:10.1523/JNEUROSCI.3863-06.
2006
75. Zhang F, Wang LP, Brauner M,
Liewald JF, Kay K, Watzke N,
et al. Multimodal fast optical
interrogation of neural circuitry.
Nature (2007) 446:633–9. doi:10.
1038/nature05744
76. Deisseroth K. Optogenetics. Nat
Methods (2011) 8:26–9. doi:10.
1038/nmeth.f.324
77. Ramirez S, Liu X, Lin PA, Suh
J, Pignatelli M, Redondo RL,
et al. Creating a false mem-
ory in the hippocampus. Science
(2013) 341:387–91. doi:10.1126/
science.1239073
78. Hashimoto K, Ishima T. A novel
target of action of minocycline
in NGF-induced neurite outgrowth
in PC12 cells: translation initia-
tion [corrected] factor eIF4AI. PLoS
One (2010) 5:e15430. doi:10.1371/
journal.pone.0015430
79. Garrido-Mesa N,Zarzuelo A,Galvez
J. What is behind the non-antibiotic
properties of minocycline? Phar-
macol Res (2013) 67:18–30. doi:10.
1016/j.phrs.2012.10.006
80. Lavisse S, Guillermier M, Her-
ard AS, Petit F, Delahaye M, Van
Camp N, et al. Reactive astro-
cytes overexpress TSPO and are
detected by TSPO positron emis-
sion tomography imaging. J Neu-
rosci (2012) 32:10809–18. doi:10.
1523/JNEUROSCI.1487-12.2012
81. Ogawa S,Lee TM,Kay AR,Tank DW.
Brain magnetic resonance imaging
with contrast dependent on blood
oxygenation. Proc Natl Acad Sci U S
A (1990) 87:9868–72. doi:10.1073/
pnas.87.24.9868
82. Raichle ME, Macleod AM, Snyder
AZ, Powers WJ, Gusnard DA, Shul-
man GL. A default mode of brain
function. Proc Natl Acad Sci U S
A (2001) 98:676–82. doi:10.1073/
pnas.98.2.676
83. Chang L, Munsaka SM, Kraft-Terry
S, Ernst T. Magnetic resonance
spectroscopy to assess neuroin-
flammation and neuropathic pain.
J Neuroimmune Pharmacol (2013)
8:576–93. doi:10.1007/s11481-013-
9460-x
84. Rothermundt M, Ohrmann P, Abel
S, Siegmund A, Pedersen A, Ponath
G, et al. Glial cell activation in a
subgroup of patients with schiz-
ophrenia indicated by increased
S100B serum concentrations and
elevated myo-inositol. Prog Neu-
ropsychopharmacol Biol Psychia-
try (2007) 31:361–4. doi:10.1016/j.
pnpbp.2006.09.013
85. Ende G, Hermann D, Demirakca T,
Hoerst M, Tunc-Skarka N, Weber-
Fahr W, et al. Loss of control of
alcohol use and severity of alco-
hol dependence in non-treatment-
seeking heavy drinkers are related
to lower glutamate in frontal white
matter. Alcohol Clin Exp Res (2013)
37:1643–9. doi:10.1111/acer.12149
86. Wergeland S, Torkildsen O, Myhr
KM, Mork SJ, Bo L. The cuprizone
model: regional heterogeneity
of pathology. APMIS (2012)
120:648–57. doi:10.1111/j.1600-
0463.2012.02882.x
87. Seki Y, Kato TA, Monji A, Mizoguchi
Y, Horikawa H, Sato-Kasai M, et al.
Pretreatment of aripiprazole and
minocycline, but not haloperidol,
suppresses oligodendrocyte dam-
age from interferon-γ-stimulated
microglia in co-culture model.
Schizophr Res (2013) (in press). doi:
10.1016/j.schres.2013.09.011
Frontiers in Psychiatry | Neuropsychiatric Imaging and Stimulation October 2013 | Volume 4 | Article 139 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kato et al. Mind-brain translation by neuron-glia interaction
88. Biswal B, Yetkin FZ, Haughton VM,
Hyde JS. Functional connectivity in
the motor cortex of resting human
brain using echo-planar MRI.
Magn Reson Med (1995) 34:
537–41. doi:10.1002/mrm.
1910340409
89. Damoiseaux JS, Rombouts SA,
Barkhof F, Scheltens P, Stam CJ,
Smith SM, et al. Consistent resting-
state networks across healthy sub-
jects. Proc Natl Acad Sci U S A
(2006) 103:13848–53. doi:10.1073/
pnas.0601417103
90. Toosy AT, Ciccarelli O, Parker
GJ, Wheeler-Kingshott CA, Miller
DH, Thompson AJ. Character-
izing function-structure relation-
ships in the human visual sys-
tem with functional MRI and dif-
fusion tensor imaging. Neuroimage
(2004) 21:1452–63. doi:10.1016/j.
neuroimage.2003.11.022
91. Greicius MD, Supekar K, Menon
V, Dougherty RF. Resting-
state functional connectivity
reflects structural connectivity
in the default mode network.
Cereb Cortex (2009) 19:72–8.
doi:10.1093/cercor/bhn059
92. Denier N, Walter M, Bendfeldt
K, Lang U, Borgwardt S. Rest-
ing state abnormalities in psy-
chosis compared to acute cannabi-
noids and opioids challenges: a
systematic review of functional
imaging studies. Curr Pharm Des
(2012) 18:5081–92. doi:10.2174/
138161212802884717
93. Jung WH, Borgwardt S, Fusar-Poli
P, Kwon JS. Gray matter volumetric
abnormalities associated with the
onset of psychosis. Front Psychia-
try (2012) 3:101. doi:10.3389/fpsyt.
2012.00101
94. Smieskova R, Allen P, Simon A,
Aston J, Bendfeldt K, Drewe J, et al.
Different duration of at-risk men-
tal state associated with neurofunc-
tional abnormalities. Hum Brain
Mapp (2012) 33:2281–94. doi:10.
1002/hbm.21360
95. Vierbuchen T, Ostermeier A, Pang
ZP, Kokubu Y, Sudhof TC, Wernig
M. Direct conversion of fibroblasts
to functional neurons by defined
factors.Nature (2010) 463:1035–41.
doi:10.1038/nature08797
96. Pang ZP, Yang N, Vierbuchen T,
Ostermeier A, Fuentes DR,Yang TQ,
et al. Induction of human neuronal
cells by defined transcription fac-
tors. Nature (2011) 476:220–3. doi:
10.1038/nature10202
97. Pfisterer U, Kirkeby A, Torper O,
Wood J, Nelander J, Dufour A,
et al. Direct conversion of human
fibroblasts to dopaminergic neu-
rons. Proc Natl Acad Sci U S A
(2011) 108:10343–8. doi:10.1073/
pnas.1105135108
98. Qiang L, Fujita R, Yamashita
T, Angulo S, Rhinn H, Rhee
D, et al. Directed conversion of
Alzheimer’s disease patient skin
fibroblasts into functional neurons.
Cell (2011) 146:359–71. doi:10.
1016/j.cell.2011.07.007
99. Yoo AS, Sun AX, Li L, Shche-
glovitov A, Portmann T, Li Y, et
al. MicroRNA-mediated conversion
of human fibroblasts to neurons.
Nature (2011) 476:228–31. doi:10.
1038/nature10323
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 20 August 2013; accepted: 07
October 2013; published online: 21 Octo-
ber 2013.
Citation: Kato TA,Watabe M and Kanba
S (2013) Neuron-glia interaction as a
possible glue to translate the mind-
brain gap: a novel multi-dimensional
approach toward psychology and psy-
chiatry. Front. Psychiatry 4:139. doi:
10.3389/fpsyt.2013.00139
This article was submitted to Neuropsy-
chiatric Imaging and Stimulation, a
section of the journal Frontiers in Psychi-
atry.
Copyright © 2013 Kato, Watabe and
Kanba. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) or licensor are cred-
ited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use, dis-
tribution or reproduction is permitted
which does not comply with these terms.
www.frontiersin.org October 2013 | Volume 4 | Article 139 | 7
